ImageneBio, Inc. (IMA) company profile
Close on Nov 16, 2026Market cap $36.32MP/E –Yield –
About ImageneBio
Biological Products, (No Diagnostic Substances), SIC 2836
ImageneBio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company's lead product candidate is IMG-007, an investigational non-depleting anti-OX40 monoclonal antibody designed to selectively bind the OX40 receptor on activated T cells to block interactions with the OX40 ligand. Through this mechanism, the candidate attenuates pathological T-cell signaling across multiple inflammatory pathways without depleting T cells. ImageneBio focuses its initial clinical development of IMG-007 on patients with atopic dermatitis, while exploring potential utility in additional conditions such as alopecia areata, asthma, rheumatoid arthritis, and hidradenitis suppurativa.
The company conducts clinical trials across multiple countries, including an ongoing dose-finding Phase 2b clinical trial evaluating IMG-007 in patients with atopic dermatitis across sites in North America and other international locations. ImageneBio maintains its principal executive offices in San Diego, California.
Summary of the business section of ImageneBio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ImageneBio, Inc.
- Headquarters
- San Diego, CA
- Address
- 12526 High Bluff Drive 92130
- Phone
- (857) 343-8292
- Website
- imagenebio.com
- Employees
- 15, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Diego, California
Stock & identifiers
- Ticker
- IMA
- Former tickers
- IKNA until Jul 25, 2025
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2021
- Shares outstanding
- 11M, Jul 31, 2026
- Public float
- $41.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-12 reverse, Jul 28, 2025
- SEC CIK
- 1835579
- CUSIP
- 45175G207
- ISIN
- US45175G2075
- FIGI
- BBG00XZY4TG9
- Share class FIGI
- BBG00XZY4TH8
- EIN
- 81-1697316
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kristin Yarema | Chief Executive Officer, Director | 493,705 |
| Yanina Grant-Huerta | Chief Financial Officer | 65,000 |
| Robert B. Lally | Principal Accounting Officer | 55,582 |
| Benjamin Porter-Brown | Chief Medical Officer | – |
| Erin Butler | Principal Accounting Officer | 25,551 |
| Yufang Lu | Chief Medical Officer | – |
| Jotin Marango | Chief Financial Officer | 15,776 |
| Joseph P. Slattery | Director | 16,000 |
| Otello Stampacchia | Director | 455,361 |
| David P. Bonita | Director | 753,441 |
| Jonathan Jian Wang | Director | 1,115,005 |
| Wei-guo Su | Director | – |
| Advisors Llc Orbimed | Director | 287,885 |
| Capital GP VI LLC OrbiMed | Director | 2,251,218 |
| Genesis GP LLC OrbiMed | Director | 753,062 |
| Stephen Hui Wang | Director | 250,721 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Kristin Yarema, Ph.D. Chief Executive Officer | $274.62K | $291.92K | $1.31M | $6.15M | $138.08K | $5.73K | $8.17M | – |
| Mark Manfredi, Ph.D. Former President and Chief Executive Officer | $338.75K | $890.00K | – | – | – | $1.48M | $2.71M | +126% |
| YuFang Lu, M.D., Ph.D. Former Chief Medical Officer | $452.01K | – | – | – | – | $195.84K | $647.85K | – |
| Jotin Marango, M.D., Ph.D. Former Chief Financial Officer | $392.61K | $905.00K | – | – | – | $271.63K | $1.57M | +4% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 26, 2021
- Offer price
- $16.00
- Securities offered
- 7,812,500
- Gross proceeds
- $125.00M
- Exchange
- Nasdaq
- First trading day
- Mar 26, 2021
- First-day close
- $32.00+100.0%
- Lock-up ends (est.)
- Sep 22, 2021
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 15 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 12, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 5, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jul 29, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 25, 2025 | Name change | Name changed from Ikena Oncology, Inc. to ImageneBio, Inc. |
| Mar 18, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 7, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 30, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 26, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?